Context Therapeutics Inc. (CNTX)
Nasdaq · Healthcare · Biotechnology
$0.3365+8.65%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $30.9M
- 52-week range
- $0.297 – $3.62
- 52-week change
- −72.57%
- EPS (trailing)
- −$0.48
Fiscal year to Dec 2025
- Net income
- −$36.1M
- Diluted EPS
- −$0.38
- Free cash flow
- −$26.4M
From the company’s annual report on SEC EDGAR.
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Headquarters: Philadelphia, United States · 15 employees · contexttherapeutics.com